Introduction
============

The link between guideline adherence, in terms of performed process measures, and clinical outcomes is a highly demanded issue in diabetes care. Diabetes is one of the leading health problems in the 21st century and requires continuous medical care, patients' self-management, and risk reduction strategies.[@b1-ppa-10-223]--[@b3-ppa-10-223] Several multidisciplinary expert committees, including the American Diabetes Associations, the European Society of Cardiology, and the European Association for the Study of Diabetes, report and adapt annually clinical guidelines to improve diabetes outcomes.[@b3-ppa-10-223],[@b4-ppa-10-223] In view of the big discussion on how to measure guideline adherence, evidence suggests that intermediate outcomes such as hemoglobin A~1c~ (HbA~1c~) can be improved and complications of diabetes can be reduced by controlling for even a simple set of performance measures such as HbA~1c~, blood pressure, and low-density lipoprotein (LDL) cholesterol.[@b5-ppa-10-223]--[@b8-ppa-10-223] However, only few data exist on the adherence to guidelines and its effect on further important clinical outcomes. While studies have shown that the adherence to guidelines has a positive impact on all-cause mortality, the effect on the risk of hospitalization has not been well studied.[@b9-ppa-10-223],[@b10-ppa-10-223] One study found an association between the adherence to screening guidelines and the hospitalization for complications with diabetes using an outdated (1994--1999) and limited sample of Medicare enrollees aged over 65 years.[@b11-ppa-10-223] Another study with diabetes patients living in a city of north-west Italy and aged 36--80 years showed that adherence was associated with reduced hospitalizations.[@b12-ppa-10-223] Thus, it is not clear how the performance of the most important process measures in diabetes care affects the risk of hospitalization in a large population of elderly and nonelderly patients with diabetes. Furthermore, we assume that it is crucial to differentiate the patients according to drug treatment, since physicians' awareness and therefore guideline adherence increased with therapy intensity. Therefore, the purpose of this study was to examine the adherence to established diabetes guidelines using a set of simple performance measures at individual patient level, and its impact on subsequent hospitalization by differentiating patients by drug treatment. To do so, we used health care claims data for retrospective cohort reflecting a large population with diabetes.

Materials and methods
=====================

Study design and study population
---------------------------------

This study was based on health care claims data from a large health insurance group in Switzerland (Helsana) covering about 1.2 million residents with mandatory health insurance. Claims files contained information on the enrollees' age, sex, health insurance plan, date of hospitalization, and prescribed drugs including the ingredients as defined by the Anatomical Therapeutic Chemical (ATC) code from the World Health Organization.[@b13-ppa-10-223] The health insurance plan was characterized by the choice of a managed care model and the chosen deductible class. As managed care models, we defined health plans with capitation, family doctor models, or telemedicine models. Deductibles are compulsory for all Swiss residents and range from Swiss Francs (CHF) 300 to CHF 2,500 per year. The standard deductible is CHF 300, but insured persons can choose a higher deductible (CHF 500, 1,500, 2,000, and 2,500) in exchange for reduced premiums. We performed a retrospective cohort study including all adult persons who were identified as patients with diabetes mellitus, continuously insured, and alive between 2011 (baseline) and 2013 (follow-up). In order to display the temporal sequence of adherence and hospitalization, we determined patients' guideline adherence by including all eligible patients with diabetes between January 1, 2011 and December 31, 2011, and estimated patients' future hospitalization risk on the basis of patients who were still eligible between January 1, 2013 and December 31, 2013. According to the national ethical and legal regulation, an ethical approval was not needed. A written informed patient consent was also not obtained for this study.

Identification of patients with diabetes
----------------------------------------

Treated patients were classified as all persons with at least one drug item for diabetes (oral blood glucose-lowering drug \[ATC code A10B\] or insulin \[ATC code A10A\]) in the baseline year. According to their drug treatment, we differentiated patients with insulin-dependent from those with noninsulin-dependent diabetes by dividing the sample into three groups: 1) patients using oral antidiabetic agents (OAs), 2) patients using insulin, and 3) patients using OAs and insulin in combination. Additionally, we considered patients' drug treatment with antihypertensives (ATC code C02/C07/C08/C09) and lipid-lowering agents (ATC code C10) as an indicator for the occurrence of the typical comorbid chronic conditions "hypertension" and "hyperlipidemia".

Definition of adherence to guidelines
-------------------------------------

Extracted from the American Diabetes Association recommendations, we identified a set of performance measures reflecting the adherence to guidelines in diabetes care. The set of four performance measures included the frequency of HbA~1c~ measurements, lipid profile (total cholesterol and/or high-density lipoprotein and/or LDL cholesterol and triglycerides), nephropathy status (serum creatinine, albuminuria), and measurement and the frequency of ophthalmologist visits.[@b3-ppa-10-223] Testing the HbA~1c~ was seen as suitable if at least two measurements per patient were performed in 2011, while the other performance measures were defined as adequate if at least one measurement or consultation were conducted in 2011. Good diabetes care in terms of good guideline adherence was seen when all criteria were fulfilled simultaneously. However, to give an insight on how the distribution of the (non)adherent patients looks, the different criteria were broken down into a total of five adherence levels. Thus, a hierarchical model of adherence to guidelines was developed by assigning each performance measure stepwise to an adherence level. The five adherence levels were defined as follows: level 0 was defined as "nonadherent", level 1 included "at least two measurements of HbA~1c~", level 2 contained "level 1 and lipid profile", level 3 included "level 2 and nephropathy status", and level 4 was defined as "receiving all performance measures including ophthalmologist visits" ([Figure 1](#f1-ppa-10-223){ref-type="fig"}). Thereby a biannual HbA~1c~ measurement was defined as the minimal criterion for guideline adherence. HbA~1c~ testing is the most commonly used measure and preferred standard to monitor glycemic control and represents an indicator to predict complications in patients with diabetes. Consequently, we began with level 0 defined as no or only one HbA~1c~ test per year and no other measurement.

Statistical analysis and outcome
--------------------------------

We used descriptive statistics to characterize the patient group and to examine the performed process measures and the occurrence of hospitalization at baseline. The outcome of interest was all-cause hospitalization in 2013 (follow-up), defined as an overnight hospital stay or a hospital stay of at least 24 hours within the given year. The proportion of patients, who were hospitalized at follow-up, was calculated for each adherence level. We used chi-square tests to compare the differences in the proportions of patients between the three drug treatment groups (OAs, insulin, and OAs and insulin in combination). To predict the probability of hospitalization at follow-up (2013) by the adherence levels of patients with diabetes at baseline (2011), we calculated adjusted odds ratios (OR) and 95% confidence intervals (CI) using multivariate logistic regression models. Regression analyses were controlled for age, sex, health insurance status, hospitalization in 2011, drug treatment group, drugs used for the treatment of comorbid hypertension and hyperlipidemia, and included an interaction term between adherence level and drug treatment group. The ORs of hospitalization as function of adherence level for the different treatment groups were displayed in a figure. Therefore, we performed two models including the same variables, the first one with adherence in its original scale (as factor) and the second one with adherence treated as interval scaled variable to display the log-linear associations by treatment group. We calculated the effect of adherence levels for the three treatment groups as well as the pairwise differences. *P*-values for all regression model results were calculated with adjustment for multiple comparisons. Data were analyzed using R, version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria), multiple testing was performed with the supplementary package "multcomp" for multiple testing applying the default comparison procedure.[@b14-ppa-10-223] *P*\<0.05 was taken to indicate statistical significance.

Results
=======

Patient characteristics
-----------------------

Of the 40,285 patients included in this cohort, most were males (55.1%), over 60 years (74.8%), had a low deductible class (95.4%), and were not enrolled in a managed care model (69.8%; [Table 1](#t1-ppa-10-223){ref-type="table"}). Almost 77% received at least one prescription for antihypertensive drugs and 52.4% received a lipid-lowering agent. Overall, 70.5% were classified as treated with OAs, 12.3% with insulin, and 17.2% with OAs and insulin in combination. In every patient group, about three-quarters of patients were aged 60 years and older, with exception of insulin-treated patients who had a significantly higher proportion of those aged under 60 years (41.1%; *P*\<0.001). The hospitalization rate at follow-up (2013) was lower in patients using OAs than in patients using insulin and in those using OAs and insulin in combination (26.5% vs 31.7% and 31.5%, respectively; *P*\<0.001).

Performance measures and adherence to guidelines
------------------------------------------------

The percentages of patients with performed process measures in diabetes care are reported in [Table 2](#t2-ppa-10-223){ref-type="table"}. About 88% of all patients had at least one annual HbA~1c~ measurement. While 59.0% of patients had an assessment of the lipid profile, only 19.8% had undergone a LDL cholesterol test. More than three-quarters of patients had a serum creatinine test, 13.1% had undergone an albuminuria test, and only 12.0% had both nephropathy measurements, and 44.2% visited an ophthalmologist. With exception of the LDL cholesterol test, statistically significant differences between the different drug treatment groups were found for all performance measures. Almost 92% of patients treated with OAs and insulin in combination had at least one annual HbA~1c~ measurement, whereas only 86.6% of patients using OAs received this process measure. Furthermore, the proportion of patients visiting an ophthalmologist differs substantially between the patient group "OAs" with 41.2% and the groups "insulin" and "OAs and insulin in combination" with about 52%.

Approximately 30% of all patients with diabetes were exposed to nonadherence (level 0). In 24.0% of patients, HbA~1c~ was measured twice a year (level 1). The highest proportion of patients exposed to nonadherence was found at level 2 including at least two HbA~1c~ measurements in a year and an annual lipid profile (37.0%). About 4% had in addition to level 2 a yearly nephropathy status (level 3) and only 4.8% were exposed to the full adherence level (level 4), which additionally comprised an annual ophthalmologist visit. Patients treated with OAs were the group with the highest percentage of patients exposed to nonadherence (OAs: 32.9% vs insulin: 27.0% and OAs and insulin in combination: 20.1%; *P*\<0.001). Compared with patients treated with OAs and those with OAs and insulin combined, insulin users had the highest proportion of patients exposed to full adherence (level 4; insulin: 7.7% vs OAs: 3.7% and OAs and insulin in combination: 7.2%; *P*\<0.001).

Adherence and subsequent hospitalization
----------------------------------------

[Table 3](#t3-ppa-10-223){ref-type="table"} shows the proportion of patients exposed to (non) adherence in 2011 with a hospitalization in 2013. Almost one-third of the hospitalized patients were exposed to nonadherence and about 7% of the patients with hospitalization had at least an adherence level of 3. Of the patients exposed to nonadherence, 28.2% were hospitalized, whereas only 19.4% of the full adherent persons (level 4) had a hospital stay (results not shown). The proportion of hospitalized patients using OAs and those using insulin decreased significantly with the adherence levels from over 30% (OAs: 35.3%; insulin: 32.2%) among the patients exposed to nonadherence to 2.8% (OAs) and 5.7% (insulin), respectively among the patients exposed to full adherence (level 4; *P*\<0.001).

The ORs of hospitalization in 2013 as a function of adherence level in 2011 for the different treatment groups, including the interaction term "adherence level-drug treatment group" and adjusted for multiple testing, are shown in [Table 4](#t4-ppa-10-223){ref-type="table"} and [Figure 2](#f2-ppa-10-223){ref-type="fig"}. The interaction term was statistically significant (*P*=0.02; result not shown). [Table 5](#t5-ppa-10-223){ref-type="table"} shows the results of the model using adherence level as interval scaled variable, which tested the statistical significance of the trends. A significant decreasing trend in the log-odds of hospitalization by adherence level could be observed in all treatment groups ([Table 5](#t5-ppa-10-223){ref-type="table"}; *P*\<0.001). This linear trend is displayed by thin lines in [Figure 2](#f2-ppa-10-223){ref-type="fig"}. For the patients treated with insulin, the ORs for hospitalization decreased with each additional level of adherence by a factor of 0.87 (95% CI: 0.81--0.94). Accordingly, the decrease of the ORs was 0.93 (95% CI: 0.90--0.97) among patients treated with OAs and 0.84 (95% CI: 0.79--0.90) among those treated with OAs and insulin in combination. When comparing the trends between the treatment groups, the effect of adherence on the hospitalization risk was strongest in patients treated with OAs and insulin in combination. However, the effect in this treatment group is only significantly greater than the effect of the treatment group with OAs only (*P*=0.002). The other two differences in trends were not significantly different.

Discussion
==========

Our study revealed four findings. First of all, physicians' guideline adherence, reflected by a simple set of performance measures was quite low. Second, adherence increased with a more intensified therapy and severity of diabetes. Third, guideline adherence predicted the risk of hospitalization. And finally, the effect size of the association between adherence and hospitalization risk depended on the therapy intensity.

Surprisingly, only a small percentage of patients (5%) were exposed to full adherence including the performance of all recommended process measures. About 30% of patients were considered as exposed to nonadherence and did not receive at least a biannual HbA~1c~ measurement. These results are consistent with prior research, which highlighted the poor guideline adherence in diabetes care, especially in the case of the HbA~1c~ measurement as the most important measure in the diabetes management.[@b15-ppa-10-223],[@b16-ppa-10-223] Results from an US study showed that only 70% of patients with diabetes received an annual HbA~1c~ measurement and a large cohort study from Luxembourg reported that even 55% of patients had no HbA~1c~ test within a year.[@b15-ppa-10-223],[@b16-ppa-10-223] Furthermore, our study revealed a poor adherence with 20% in the measurement of LDL cholesterol, which is classified as an essential parameter in testing lipid profile in national as well as in international recommendations in diabetes care.[@b4-ppa-10-223],[@b17-ppa-10-223] Previous studies from Switzerland also suggested a suboptimal performance of HbA~1c~ measurement and lipid profile assessment, but showed higher adherence levels in lipid profile assessment than in our study. Bovier et al,[@b18-ppa-10-223] reported HbA~1c~ measurements three times a year for 65% and a yearly lipid profile assessment for 89% in a diabetes sample of 400 patients in the French-speaking part of Switzerland. A further study showed that 84% had a biannual HbA~1c~ measurement among HbA~1c~ aware patients and 94% had undergone a lipid profile assessment.[@b19-ppa-10-223] However, comparability to our findings is limited since previous studies were based on patients' self-reporting, older data, or on selected medical files of a small diabetes sample and not on a large general population of persons with diabetes. Most patients achieved only adherence level 2 including at least two HbA~1c~ measurements and a lipid profile assessment. The proportion of patients with an additional nephropathy status (level 3) and ophthalmologist consultation (level 4) decreased significantly.

Therapy intensity, reflected in an additional insulin therapy or insulin therapy only was associated with an increased guideline adherence: we found the highest proportion of patients receiving care according to level 4 (full adherence) in insulin users, followed by those with combined therapy (OA agents and insulin). We suppose that with increased disease severity, reflected in an intensified therapy, physicians' awareness and therefore guideline adherence increased.

The major finding of our study is that it provides evidence that the adherence to medical standards in diabetes care led to a significantly decreased probability of future hospitalization among patients. An interaction between adherence levels and drug treatment group was found showing different trends for the treatment groups. The hospitalization risk for the treatment group with OAs was for low adherence levels considerably smaller than for the other two treatment groups. The effect size of the association between adherence and hospitalization risk was significantly stronger in the OAs group compared with the treatment group with OAs and insulin in combination. The association between adherence to guidelines and reduced rates of hospitalization was also found in the study by Sloan et al.[@b11-ppa-10-223] Only few comparable population-based studies examining the impact of adherence to medical standards on outcomes such as hospitalization are available, particularly those using performed process measures as indicator for the adherence to guidelines. Most studies predicting health outcomes such as hospitalization or mortality are focused on oral antihyperglycemic medication adherence.[@b20-ppa-10-223]--[@b23-ppa-10-223]

In this context, it is important to acknowledge that guideline adherence in our study was defined by simple performance measures. Our results suggest that even this simple measurement, which could be easily calculated from health care claims data, is able to predict outcomes such as hospitalization. In Switzerland -- as in many countries -- there is a huge discussion on how to measure quality of care in ambulatory care. Our results suggest that already available datasets could help to reflect quality of care and therefore help to improve it.

Several strengths and limitations of our study have to be taken into account. The main strength is that the study was based on very comprehensive health care claims data, which covers a large population-based cohort of patients with diabetes. Health care claims data are a reliable and practice-based information source, and they are particularly valuable when data from population-based disease studies are lacking. Our findings confirm that claims-based adherence measures are good indicators to determine patients' health care behavior and are additionally valuable predictors for health care utilization. The study also has several limitations. First, the number of patients with diabetes may be biased, because clinical diagnoses (eg, ICD-10) were not available, and undiagnosed patients without medication but with lifestyle treatment could not be included in the study. However, we assume that this potential bias is negligible, since diagnoses based on dispensed drugs are a valid proxy for clinical diagnoses and in the meanwhile widely used in epidemiological and outcomes research to estimate diabetes prevalence.[@b24-ppa-10-223],[@b25-ppa-10-223] Second, since we used the World Health Organization ATC codes to identify patients with diabetes, we were unable to distinguish between type 1 and type 2 diabetes. However, according to epidemiological data, it is assumed that \~90% of patients with diabetes were classified with type 2 diabetes. Moreover, since patients with type 1 diabetes are mostly younger persons (≤18 years), and we included only adult patients, the majority of our study sample most likely comprised patients with type 2 diabetes.[@b26-ppa-10-223] Third, the used data did not allow us to investigate long-term effects of poor adherence on health outcomes, thus it would be clinically important to examine a longer observation period in future studies. Fourth, our data did not include further information on clinical parameters such as laboratory values, duration of diabetes, and cardiovascular risk factors (ie, blood pressure and body weight). Although our analysis was adjusted for numerous variables indicating patients' disease severity (kind of drug treatment) or comorbidities (eg, using drugs for hypertension), our information on the severity of diabetes and the overall health status is limited. A poor health status can act as confounder in our analyses. Since the frequency of health care use strongly depends on the disease severity, an underestimation of the positive impact on guideline adherence cannot be excluded. Fifth, the analyses criteria were process indicators and not intermediate ones. Guideline adherence has therefore to be considered as a proxy for better care in terms of better communication, education, or methodological approach. Finally, according to the given cohort study design, we had to exclude dead or ineligible persons from the study population. Therefore, the impact of guideline adherence and hospitalization risk applies only to persons who survive long enough to measure the adherence and its potential effect on future outcomes.

Conclusion
==========

This study showed that health care claims data can be used to calculate a simple set of performance measures to observe adherence of provided care to established guideline recommendations. Furthermore, a clear relation between adherence levels and the hospitalization probability of diabetes patients could be proven. Regarding the low performance in the observed measures, our study emphasizes the need to foster the implementation of evidence in daily treatment of diabetes patients. Simple measures provided in this study seem to be able to enable this.
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![Classification of adherence levels.\
**Note:** The adherence levels were measured per patient in 2011.\
**Abbreviations:** HbA~1c~, hemoglobin A~1c~; HDL, high-density lipoprotein; LDL, low-density lipoprotein.](ppa-10-223Fig1){#f1-ppa-10-223}

![Odds ratios of hospitalization as a function of adherence level by treatment group.\
**Note:** The thin lines represent the linear trend.\
**Abbreviations:** OAs, oral antidiabetic agents; OR, odds ratio.](ppa-10-223Fig2){#f2-ppa-10-223}

###### 

Patients characteristics of the diabetes cohort by drug treatment group at baseline

  Characteristic                                              Total n=40,285   Users of OAs n=28,404   Users of insulin n=4,965   Users of OAs and insulin in combination n=6,916   *P*-value[a](#tfn1-ppa-10-223){ref-type="table-fn"}
  ----------------------------------------------------------- ---------------- ----------------------- -------------------------- ------------------------------------------------- -----------------------------------------------------
  **Population characteristics and hospitalization (2011)**                                                                                                                         
  Sociodemographics                                                                                                                                                                 
   Male                                                       55.1             54.6                    55.4                       56.7                                              0.005
   Age group (years)                                                                                                                                                                \<0.001
    18--39                                                    2.9              1.3                     14.0                       1.9                                               
    40--59                                                    22.3             21.0                    27.1                       23.7                                              
    60--79                                                    58.2             60.4                    42.5                       60.6                                              
    \>79                                                      16.6             17.3                    16.4                       13.8                                              
  Health insurance status                                                                                                                                                           
   Managed care model                                         30.2             31.7                    25.9                       27.0                                              \<0.001
   Deductible                                                                                                                                                                       \<0.001
    High (\>CHF 500)                                          4.6              5.3                     2.6                        3.0                                               
    Low (CHF 300/500)                                         95.4             94.7                    97.4                       97.1                                              
  Hospitalization                                             23.4             20.5                    29.4                       30.9                                              \<0.001
  Use of antihypertensive drugs                               76.5             77.0                    63.9                       83.5                                              \<0.001
  Use of lipid-lowering drugs                                 52.4             51.1                    45.0                       62.8                                              \<0.001
  **Hospitalization (2013)**                                  25.9             26.5                    31.7                       31.5                                              \<0.001

**Note:**

*P*-values refer to chi-square test across the three drug treatment groups.

**Abbreviations:** CHF, Swiss Francs; OAs, oral antidiabetic agents.

###### 

Adherence to recommended diabetes care guidelines by drug treatment group

  Measure of adherence (2011)                                            Total   Users of oral OAs   Users of insulin   Users of OAs and insulin in combination   *P*-value[a](#tfn3-ppa-10-223){ref-type="table-fn"}
  ---------------------------------------------------------------------- ------- ------------------- ------------------ ----------------------------------------- -----------------------------------------------------
  **Performance measures**                                                                                                                                        
   Annual HbA~1c~ measurement                                            87.6    86.6                87.3               91.8                                      \<0.001
  Annual lipid profile                                                                                                                                            
   Annual total cholesterol test                                         65.2    66.6                58.3               64.2                                      \<0.001
   Annual HDL cholesterol test                                           56.5    57.5                52.1               55.9                                      \<0.001
   Annual LDL cholesterol test                                           19.8    19.9                19.0               20.1                                      0.317
   Annual triglycerides test                                             59.0    60.0                54.0               58.5                                      \<0.001
   Annual lipid profile (total cholesterol/HDL/LDL, and triglycerides)   59.0    59.9                54.0               58.3                                      \<0.001
  Annual nephropathy status                                                                                                                                       
   Annual serum creatinine test                                          77.4    76.7                76.6               80.6                                      \<0.001
   Annual albuminuria test                                               13.1    11.6                17.0               16.6                                      \<0.001
   Annual nephropathy status (serum creatinine and albuminuria)          12.0    10.6                15.5               15.4                                      \<0.001
  Annual visit to an ophthalmologist                                     44.2    41.2                51.4               51.5                                      \<0.001
  **Adherence level**                                                                                                                                             
  Nonadherent (level 0)                                                  29.9    32.9                27.0               20.1                                      \<0.001
  ≥2 HbA~1c~ measurements in a year (level 1)                            24.0    22.3                27.3               28.7                                      
  Level 1 and annual lipid profile (level 2)                             37.0    37.1                33.7               39.1                                      
  Level 2 and nephropathy status (level 3)                               4.3     4.1                 4.3                5.0                                       
  Level 3 and visit to an ophthalmologist (level 4)                      4.8     3.7                 7.7                7.2                                       

**Note:**

*P*-values refer to chi-square test across the drug treatment groups.

**Abbreviations:** HbA~1c~, hemoglobin A~1c~; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OAs, oral antidiabetic agents.

###### 

Proportion of patients hospitalized in 2013 by adherence level and drug treatment in 2011

                                                      Hospitalization (2013)                        
  --------------------------------------------------- ------------------------ ------ ------ ------ ---------
  **Adherence level (2011)**                                                                        
  Nonadherent (level 0)                               32.7                     35.3   32.2   24.9   \<0.001
  ≥2 HbA~1c~ measurement in a year (level 1)          26.9                     25.0   29.6   30.9   
  Level 1 and annual lipid profile (level 2)          33.6                     33.7   29.6   36.3   
  Level 2 and nephropathy status (level 3)            3.2                      3.2    2.9    3.4    
  Level 3 and visit to an ophthalmologist (level 4)   3.6                      2.8    5.7    4.5    

**Note:**

*P*-values refer to chi-square test across the drug treatment groups.

**Abbreviations:** HbA~1c~, hemoglobin A~1c~; OAs, oral antidiabetic agents.

###### 

Prediction of hospitalization by adherence level (as factor variable), including the interaction term "adherence level-drug treatment group" and adjusting for multiple comparisons

                                                      Hospitalization (2013)                                                                                                                                                         
  --------------------------------------------------- ------------------------------------------------ ------------ ------------------------------------------------- ------------ ------------------------------------------------- ------------
  **Adherence level (2011)**                                                                                                                                                                                                         
  Nonadherent (level 0)                               1.00 (reference)                                              0.55                                              0.45--0.66   0.94                                              0.74--1.20
  ≥2 HbA~1c~ measurement in a year (level 1)          0.88                                             0.69--1.13   0.55[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.45--0.67   0.78[c](#tfn9-ppa-10-223){ref-type="table-fn"}    0.62--0.97
  Level 1 and annual lipid profile (level 2)          0.74[b](#tfn8-ppa-10-223){ref-type="table-fn"}   0.58--0.94   0.48[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.40--0.58   0.70[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.57--0.87
  Level 2 and nephropathy status (level 3)            0.57[c](#tfn9-ppa-10-223){ref-type="table-fn"}   0.34--0.96   0.47[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.35--0.62   0.54[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.36--0.83
  Level 3 and visit to an ophthalmologist (level 4)   0.64[c](#tfn9-ppa-10-223){ref-type="table-fn"}   0.43--0.95   0.39[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.29--0.53   0.43[d](#tfn10-ppa-10-223){ref-type="table-fn"}   0.30--0.63

**Notes:**

Adjusted for sociodemographics, health insurance status, hospitalization, use of antihypertensive drugs, and use of lipid lowering drugs;

*P*≤0.01;

*P*≤0.05;

*P*≤0.001.

**Abbreviations:** CI, confidence interval; HbA~1c~, hemoglobin A~1c~; OAs, oral antidiabetic agents; OR, odds ratio.

###### 

Prediction of hospitalization by adherence level (as interval scaled variable), including the interaction term "adherence level-drug treatment group" and adjusting for multiple comparisons

                                              Hospitalization (2013) by Adherence level (2011)   
  ------------------------------------------- -------------------------------------------------- ------------
  **Drug treatment group**                                                                       
  Insulin                                     0.87[b](#tfn13-ppa-10-223){ref-type="table-fn"}    0.81--0.94
  OAs                                         0.93[b](#tfn13-ppa-10-223){ref-type="table-fn"}    0.90--0.97
  OAs and insulin in combination              0.84[b](#tfn13-ppa-10-223){ref-type="table-fn"}    0.79--0.90
  OAs vs insulin                              1.07                                               0.98--1.16
  OAs and insulin in combination vs insulin   0.96                                               0.87--1.06
  OAs and insulin in combination vs OAs       0.90[c](#tfn14-ppa-10-223){ref-type="table-fn"}    0.84--0.97

**Notes:**

Adjusted for all variables in [Table 1](#t1-ppa-10-223){ref-type="table"};

*P*≤0.001;

*P*≤0.01.

**Abbreviations:** CI, confidence interval; OAs, oral antidiabetic agents; OR, odds ratio.
